Business
– Mesupron, which targets gastrointestinal and other cancers, has been licensed from Wilex. RedHill Biopharma Ltd. (Nasdaq: RDHL); TASE: RDHL) has expanded its late clinical-stage gastrointestinal-focused pipeline...
Hi, what are you looking for?
– Mesupron, which targets gastrointestinal and other cancers, has been licensed from Wilex. RedHill Biopharma Ltd. (Nasdaq: RDHL); TASE: RDHL) has expanded its late clinical-stage gastrointestinal-focused pipeline...
– Weizmann Institute scientists “fingerprint” a culprit in depression, anxiety and other mood disorders. – – According to the World Health Organization, such...
– – Technion researchers developed a novel approach for potential treatment of cancer cells that are resistant to chemotherapy Technion researchers discovered that multidrug...
– – Israel has benefited from quite a developed medicinal cannabis program since the early 1990s. According to testimonies from patients themselves, several nations...
– – U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) new dose of COPAXONE drug application (sNDA) for three-times-a-week 40mg/mL....
– – /By Johanna Weiß/ “Break a leg” may be what people say when they want to wish someone luck, but breaking a leg is...
– The Company’s VB-111 is a gene therapy for prolonging the survival in patients with recurrent Glioblastoma Multiforme (rGBM), an aggressive form of brain...
– – At the age of 78 Dr. Eli Fischer doesn’t plan to retire any time soon. He is a scientist, a successful international...
– Credit Suisse sees Copaxone sales falling from $4 billion annually to $400, 000 in 2019 and predicts annual sales of over $1 billion...
– – Israeli OphthaliX Inc. (OTC BB: OPLID), announced that the European Patent Office issued a Certificate of Grant of Patent for European Patent No....